Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib

BACKGROUND: Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an open-label phase IV trial. OBJECTIVE: To asse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Target Oncol
Hauptverfasser: Fazio, Nicola, Kulke, Matthew, Rosbrook, Brad, Fernandez, Kathrine, Raymond, Eric
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2021
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810649/
https://ncbi.nlm.nih.gov/pubmed/33411058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00784-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge